Boryeong's 'Kanabeu' Expansion Strategy Smooth Sailing... "Annual Sales to Reach 200 Billion Won by 2026"

Approval of Phase 3 Plan for 4-Drug Combination Therapy for Hypertension and Dyslipidemia
'Great Kanab' Strategy Leading with Combination Therapy

Boryung is strengthening its market dominance through an expansion strategy of the lineup for the hypertension treatment drug 'Kanarb (active ingredient Pimasartan)'.

Kanab Family, a Hypertension Treatment from Boryeong.
[Photo by Boryeong]

On the 20th, Boryung announced that it had received approval from the Ministry of Food and Drug Safety for the clinical phase 3 trial plan (IND) of 'BR1018', an improved new drug for hypertension and dyslipidemia, on the 15th. BR1018 is a four-component combination drug developed by Boryung, which adds amlodipine, atorvastatin, and ezetimibe to the main ingredient of Kanarb, pimasartan.

BR1018 will undergo clinical trials for about two years involving 156 patients with essential hypertension and primary hypercholesterolemia. Since it contains four ingredients in a single pill, Boryung explained that it expects an improvement in patient medication adherence.

Boryung has continuously launched combination drugs that combine various ingredients with Kanarb. Starting with the single-agent Kanarb in 2011, it has released ▲Kanarb Plus (pimasartan·hydrochlorothiazide) ▲Ducarb (pimasartan·amlodipine) ▲Tubero (pimasartan·rosuvastatin) ▲Ducaro (pimasartan·amlodipine·rosuvastatin) ▲Acarb (pimasartan·atorvastatin) ▲Ducarb Plus (pimasartan·amlodipine·hydrochlorothiazide). The average growth rate over the past five years has been over 23%.

According to IQVIA, last year the Kanarb product line recorded prescription sales of 141.8 billion KRW, ranking first among domestic new drugs in prescription performance. It also ranked first in prescription performance among domestic family drugs composed of single and combination agents.

Boryung has also focused on strengthening Kanarb's product competitiveness through continuous clinical research. Boryung has secured 131 papers related to Kanarb and more than 72,000 clinical cases, leading to the addition of proteinuria reduction indications and expanded usage age. Additionally, it has proven that Kanarb is effective in controlling blood pressure and reducing stroke recurrence in stroke patients.

Through the 'Great Kanarb' strategy, Boryung plans to achieve annual sales of 200 billion KRW by 2026 by continuously launching combination drugs and expanding clinical research. Currently, various Kanarb combination drugs such as the hypertension combination drug BR1015 and the hypertension and dyslipidemia combination drug BR1017 are under development, and the combination drug 'BR1019' that can simultaneously treat hypertension and diabetes has also applied for clinical phase 3 trial plans.

Im Jong-rae, head of Boryung's Research & Development (R&D) division, said, "Through continuous development of Kanarb combination drugs, we aim to provide various treatment options to prescribers and improve patient medication adherence. We will also expand investment in continuous research to enhance Kanarb's clinical excellence, such as adding new indications."

This content was produced with the assistance of AI translation services.